Industries > Pharma > Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2013-2023

Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2013-2023

PUBLISHED: 19 September 2013
PAGES: 206
PRODUCT CODE:

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: N/A Categories: , ,

Producers of biosimilars – how to assess products, developments, and revenue prospects

What does the future hold for makers of biosimilar drugs? Visiongain's updated report shows you those companies' prospects to 2023. There you see results, trends, opportunities, and revenue predictions.

Our study analyses 25 leading developers, producers and marketers of biosimilars, also with discussion of other companies. There you find information on established and rising organisations. Discover their sales potentials.

That investigation is for everyone interested in the future of biopharmaceuticals. See now how you can benefit.

Forecasts and other data to help you stay ahead in knowledge of those biological drugs

In that report you find analytical profiles of top companies worldwide. There you analyse historical data, R&D, market shares, revenue forecasts, and growth rates. See qualitative analysis too for those biologics. You also gain 97 charts, 44 tables and an interview.

That work lets you assess the most lucrative parts of the industry for biosimilar drugs. Get revenue forecasts to 2023 for eight of the companies. See there how you can benefit your research, analyses, and decisions, also saving time.

Find where money lies for those protein-based medicines. The following sections explain what you get in that new analysis.

Companies based in regions with developed pharma industries

First, our study gives you discussions, financial analyses, and commercial outlooks for six biosimilar drug producers among the leading drug-producing countries:
• Sandoz
• Teva
• Hospira
• Stada Arzneimittel
• Medice Arzneimittel Pütter
• JCR Pharmaceuticals.

You see possibilities there for business performance. Discover what the future holds for those companies, including revenue predictions to 2023 for top firms. Hear too about other companies, including Actavis, Mylan, Pfizer, Boehringer Ingelheim, Mochida, and Nichi-Iko.

China – outlooks for leading biosimilar drug manufacturers

Next, our report analyses five Chinese biosimilar specialists:
• 3SBio
• Beijing SL Pharmaceutical
• GeneScience Pharmaceuticals
• Shanghai Fosun
• Tonghua Dongbao.

Many opportunities remain, with high, expanding revenues possible from 2013. See where best potentials exist.

India – prospects for leading players

You also discover outlooks for six Indian biosimilar specialists:
• Biocon
• Dr. Reddy's Laboratories
• Intas Biopharmaceuticals
• Reliance Life Sciences
• Wockhardt
• Zydus Cadila.

You also hear about activities of Ranbaxy, Cipla, and Lupin. Our report shows you how companies seize opportunities and expand their revenues.

Latin America – analysis of leading biological drug firms

Our new work also assesses four Latin American biosimilar drug producers:
• Probiomed
• Biosidus
• Amega Biotech
• Aché.

You find revenue data, trends, and opportunities there, seeing activities, product ranges, and prospects.

Producers from Central and Eastern Europe (CEE), Russian Federation, and South Korea

You also discover outlooks and activities of companies based in other developing countries:
• Bioton
• Pharmstandard
• LG Life Sciences
• Dong-A Pharmaceutical.

Developing and developed national markets will prove important for biosimilar drug sales from 2013 to 2023, our analyses show. Discover what the future holds.

Revenue prediction for the overall biosimilars market and its submarkets

Our report also forecasts revenues to 2023 for the world biosimilars industry and seven main segments:
• EPO
• Insulin
• Filgrastim
• Somatropin
• Interferons
• FSH
• Monoclonal antibodies (mAbs).

There you see overall world revenues in 2017 reaching $8.8bn. Our analyses reveal high sales growth from 2013 to 2023. That work also predicts large companies and specialty healthcare firms will develop and prosper.

Ways Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2013-2023 helps you

In particular, our new report gives you the following knowledge:
• Profiles of 25 leading companies – assess product ranges, strategies, and sales results, also gaining revenue forecasts to 2023 for 8 organisations
• Competition and opportunities – explore what affects the biosimilars market, finding what shapes its future, esp. prospects for sustaining and developing business
• Revenues to 2023 for that industry at world level, with forecasting of 7 submarkets – discover overall outlooks for commercial success.

Analysis found nowhere else – discover the future of those biologics

Our work gives independent analysis. There you receive competitive intelligence found only in our report. You discover where prospects are most rewarding.

With that investigation you're less likely to fall behind in knowledge or miss sales opportunity. See there how you could benefit your research, analysis, and decisions. Also find how you could save time and get recognition for understanding, increasing your influence.

Predictions for developing, producing, and selling biosimilars – gain by ordering now

Our new report shows you data, trends, opportunities, and outlooks for producers and sellers of biosimilars and related biological drugs. That analysis is for everybody interested in the future of biopharmaceuticals. Avoid missing out – please order now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

To view free sample pages of this report please click here

Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2013-2023


Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2013-2023


Latest Pharma news

“Global Ophthalmic Drugs market set to grow to $32bn by 2024” says Visiongain report

Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions.

15 August 2019

READ

“Global Medical Device Contract Manufacturing market set to grow to $130bn by 2024” says new Visiongain report

The available reduced costs of outsourced manufacturing combined with access to the innovation power of CMOs are major drivers behind the decision to outsource manufacturing processes.

06 August 2019

READ

“3D Printing for Healthcare market is worth $872 million in 2019” says Visiongain report

The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient.

02 August 2019

READ

“Global Rare Disease Drugs market set to grow to $257bn by 2024” says new Visiongain report

It is difficult to investigate rare diseases as the pool of patients is very small and often results in inadequate clinical knowledge.

01 August 2019

READ

Categories

Category